• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Igc Pharma Inc (NY: IGC )

    0.4002 +0.0149 (+3.87%)
    Streaming Delayed Price Updated: 10:46 AM EDT, Oct 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Igc Pharma Inc

    < Previous 1 2 3 Next >
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts
    Via Benzinga
    IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025
    IGC stock results show that IGC Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
    Via InvestorPlace
    IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
    Via InvestorPlace
    IGC Stock Earnings: IGC Pharma Meets EPS, Beats Revenue for Q4 2024
    IGC stock results show that IGC Pharma met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2024. 
    Via InvestorPlace
    Hedge Fund Settles At $2.25M With SEC For Exposed Short Seller Deal, 2 Cannabis Stocks Affected
    Discover how Anson Funds settled with the SEC for $2.25M over an undisclosed collaboration with short seller impacting cannabis stocks 
    Via Benzinga
    Topics Cannabis Regulatory Compliance
    Exposures Cannabis Legal Regulatory
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings
    6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings 
    Via News Direct
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news for Wednesday morning! 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
    IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo. 
    Via Benzinga
    Who's Who In Cannabis: Latest Executive Changes You Should Know About
    Via Benzinga
    IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
    --News Direct-- 
    Via News Direct
    IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
    Via Benzinga
    EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
    IGC Pharma's breakthrough Alzheimer's drug, IGC-AD1, shows promising interim results in reducing cognitive and behavioral symptoms, offering hope for patients and families. Its dual-action capability... 
    Via Benzinga
    Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
    IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed. 
    Via Benzinga
    Benzinga's 2024 Virtual Healthcare: What's Next In Health?
    The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss... 
    Via Benzinga
    IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1
    --News Direct-- 
    Via News Direct
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses
    IGC Pharma's Q3 2024 results: Navigating financial dips with strategic patents in pain treatment and Alzheimer's therapy. 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Why IGC Pharma Stock Is Moving Higher
    IGC Pharma highlighted data from a trial in which the group treated with TGR-63 showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to... 
    Via Benzinga
    AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research
    IGC Pharma partners with University of Los Andes, to leverage AI for improving Alzheimer's disease treatment and clinical trial efficiency. 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Cannabis Based Pain Relief Solution Receives European Patent Approval
    IGC Pharma, Inc. (NYSE American: IGC) has been granted European Patent No. 3193862 by the European Patent Office for its innovative "Cannabinoid Composition and Method for Treating Pain." 
    Via Benzinga
    Topics Cannabis Intellectual Property
    Exposures Cannabis Intellectual Property
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.